Literature DB >> 25488611

Clinical characteristics and outcomes after 5 years pro re nata treatment of neovascular age-related macular degeneration with ranibizumab.

Archana Airody1, Divya Venugopal1, Victoria Allgar2, Richard P Gale1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25488611     DOI： 10.1111/aos.12618

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  5 in total

1.  Six-year outcomes in neovascular age-related macular degeneration with ranibizumab.

Authors:  Julie Jacob; Heidi Brié; Anita Leys; Laurent Levecq; Filip Mergaerts; Kris Denhaerynck; Stefaan Vancayzeele; Eline Van Craeyveld; Ivo Abraham; Karen MacDonald
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

Review 2.  Demographic and Clinical Factors that Influence the Visual Response to Anti-Vascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration: A Systematic Review.

Authors:  Claire R Gill; Catherine E Hewitt; Tracy Lightfoot; Richard P Gale
Journal:  Ophthalmol Ther       Date:  2020-08-08

3.  Cortical Atrophy Predicts Visual Performance in Long-Term Central Retinal Disease; GCL, pRNFL and Cortical Thickness Are Key Biomarkers.

Authors:  Rachel L W Hanson; Heidi A Baseler; Archana Airody; Antony B Morland; Richard P Gale
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-05-02       Impact factor: 4.925

Review 4.  Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence.

Authors:  Vincent Daien; Robert P Finger; James S Talks; Paul Mitchell; Tien Y Wong; Taiji Sakamoto; Bora M Eldem; Jean-François Korobelnik
Journal:  Br J Ophthalmol       Date:  2020-10-31       Impact factor: 4.638

5.  Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections.

Authors:  Richard Gale; Claire Gill; Maria Pikoula; Aaron Y Lee; Rachel L W Hanson; Spiros Denaxas; Catherine Egan; Adnan Tufail; Paul Taylor
Journal:  Br J Ophthalmol       Date:  2020-09-22       Impact factor: 4.638
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.